Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2064
Nomenclature: mitogen-activated protein kinase kinase 3
Abbreviated Name: MKK3
Family: STE7 family
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 347 | 17p11.2 | MAP2K3 | mitogen-activated protein kinase kinase 3 | |
Mouse | - | 347 | 11 B2 | Map2k3 | mitogen-activated protein kinase kinase 3 | |
Rat | - | 347 | 10 q22 | Map2k3 | mitogen activated protein kinase kinase 3 |
Previous and Unofficial Names |
dual specificity mitogen activated protein kinase kinase 3 | MAP kinase kinase 3 | MKK3 | PRKMK3 |
Database Links | |
Alphafold | P46734 (Hs), O09110 (Mm) |
BRENDA | 2.7.12.2 |
ChEMBL Target | CHEMBL2109 (Hs), CHEMBL3721303 (Mm) |
Ensembl Gene | ENSG00000034152 (Hs), ENSMUSG00000018932 (Mm), ENSRNOG00000065992 (Rn) |
Entrez Gene | 5606 (Hs), 26397 (Mm), 303200 (Rn) |
Human Protein Atlas | ENSG00000034152 (Hs) |
KEGG Enzyme | 2.7.12.2 |
KEGG Gene | hsa:5606 (Hs), mmu:26397 (Mm), rno:303200 (Rn) |
OMIM | 602315 (Hs) |
Pharos | P46734 (Hs) |
RefSeq Nucleotide | NM_145109 (Hs), NM_008928 (Mm), NM_001100674 (Rn) |
RefSeq Protein | NP_659731 (Hs), NP_032954 (Mm), NP_001094144 (Rn) |
UniProtKB | P46734 (Hs), O09110 (Mm) |
Wikipedia | MAP2K3 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 2,5 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: MEK3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
Immuno Process Associations | ||
|
||
|
General Comments |
SARS-CoV-2: p38 MAP kinase activity is reported to be upregulated by SARS-CoV-2 infection in vitro [1]. siRNA-mediated knockdown of MAP2K3 in A549-ACE2 cells significantly reduces SARS-CoV-2 replication, without reducing cell viability. |
1. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Marrero MC, Polacco BJ, Melnyk JE, Ulferts S, Kaake RM. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, Article Online Now. DOI: 10.1016/j.cell.2020.06.034
2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
3. Tang ML, Li H, Ning JF, Shen X, Sun X. (2022) Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor (R)-STU104 for the Treatment of Ulcerative Colitis through Modulating TNF-α Production. J Med Chem, 65 (9): 6690-6709. [PMID:35442672]
4. Wityak J, Hobbs FW, Gardner DS, Santella 3rd JB, Petraitis JJ, Sun JH, Favata MF, Daulerio AJ, Horiuchi KY, Copeland RA et al.. (2004) Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett, 14 (6): 1483-6. [PMID:15006386]
5. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
STE7 family: mitogen-activated protein kinase kinase 3. Last modified on 24/05/2022. Accessed on 02/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2064.